Colossal Biosciences says de-extinction work could help human health and conservation

Colossal Biosciences CEO Ben Lamm says the company's dire wolf and woolly mammoth projects could yield conservation and human health benefits, including tools for DNA synthesis and gene therapies.

Lamm says Colossal is pursuing work on the dodo, Tasmanian tiger and moa, and that it aims for a woolly mammoth birth in the 2030s. The company was valued at $10.2 billion after a $200 million Series C round in July.